Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41232   clinical trials with a EudraCT protocol, of which   6757   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-003662-40
    Sponsor's Protocol Code Number:UKER-AMGEVITA-CED-NOVO-01
    National Competent Authority:Germany - PEI
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-10-22
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - PEI
    A.2EudraCT number2019-003662-40
    A.3Full title of the trial
    Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and safety of the adalimumab biosimilar Amgevita in subjects with moderate to severe active chronic inflammatory bowel diesease (Crohn's disease and ulcerative colitis)
    Prospektive, offene, einarmige, monozentrische klinische Prüfung der Phase IV zur Untersuchung der Wirksamkeit und Sicherheit des Adalimumab Biosimilar Amgevita® bei Patienten mit mittelschwerer bis schwerer aktiver chronisch entzündlicher Darmerkrankung (Morbus Crohn und Colitis ulcerosa)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and safety of the adalimumab biosimilar Amgevita in subjects with moderate to severe active chronic inflammatory bowel diesease (Crohn's disease and ulcerative colitis)
    A.3.2Name or abbreviated title of the trial where available
    Amgevita de novo in CED
    A.4.1Sponsor's protocol code numberUKER-AMGEVITA-CED-NOVO-01
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUniversitätsklinikum Erlangen
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAmgen GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUniversitätsklinikum Erlangen
    B.5.2Functional name of contact pointMedizinische Klinik 1
    B.5.3 Address:
    B.5.3.1Street AddressUlmenweg 18
    B.5.3.2Town/ cityErlangen
    B.5.3.3Post code91054
    B.5.3.4CountryGermany
    B.5.6E-mailmarkus.neurath@uk-erlangen.de
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Amgevita 40 mg Injektionslösung in einer Fertigspritze
    D.2.1.1.2Name of the Marketing Authorisation holderAMGEN GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNADALIMUMAB
    D.3.9.1CAS number 331731-18-1
    D.3.9.4EV Substance CodeSUB20016
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Amgevita 40 mg Injektionslösung im Fertigpen
    D.2.1.1.2Name of the Marketing Authorisation holderAMGEN GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection in pre-filled pen
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNADALIMUMAB
    D.3.9.1CAS number 331731-18-1
    D.3.9.4EV Substance CodeSUB20016
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    E.1.1.1Medical condition in easily understood language
    Moderate to severe active chronic inflammatory bowel disease
    Mittelschwere bis schwere aktive chronisch entzündliche Darmerkrankung
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10021972
    E.1.2Term Inflammatory bowel disease
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To investigate efficacy of adalimumab biosimilar (Amgevita) in subjects with moderate to severe active chronic inflammatory bowel disease (Crohn's disease and ulcererative colitis)
    Nachweis der Wirksamkeit von Adalimumab-Biosimilar (Amgevita®) bei Patienten mit mittelschweren bis schweren aktiven CED (M. Crohn und Colitis ulcerosa)
    E.2.2Secondary objectives of the trial
    - To investigate efficacy of adalimumab biosimilar (Amgevita) in subjects To investigate efficacy of adalimumab biosimilar (Amgevita) in subjects with moderate to severe active chronic inflammatory bowel disease (Crohn's disease and ulcererative colitis)
    - Relation between adalimumab-auto antibody and response to therapy
    - Relation between adalimumab plasma levels and disease activity
    - Evaluation of quality of life under therapy with Amgevita
    - Estimation of disease activity in relation to fecal calprotectin level
    - safety and tolerability of adalimumab biosimilar (Amgevita) in subjects with moderate to severe active chronic inflammatory bowel disease (Crohn's disease and ulcererative colitis)
     Untersuchung der Wirksamkeit von Adalimumab-Biosimilar (Amgevita®) bei Patienten mit mittelschwerer bis schwerer aktiver CED im Untersuchungszeitraum
     Untersuchung des Zusammenhangs von Adalimumab-Autoantikörpern und Therapieansprechen
     Untersuchung des Zusammenhangs von Adalimumab-Plasmaspiegel und Krankheitsaktivität
     Beurteilung der Lebensqualität unter der Therapie mit Amgevita®
     Abschätzung der Krankheitsaktivität anhand der fäkalen Calprotectinkonzentration
     Sicherheit und Verträglichkeit von Adalimumab-Biosimilar (Amgevita®) bei Patienten mit mittelschweren bis schweren aktiven CED im Untersuchungszeitraum
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Evaluation of suitability of fMRI for the prediction of the response to adalimumab therapy early in initial treatment with the adalimumab biosimilar (Amgevita)
    Überprüfung der Eignung von fMRT zur Prädiktion des Ansprechens auf die Therapie mit Adalimumab bei Neueinstellung auf das Adalimumab-Biosimilar (Amgevita®)
    E.3Principal inclusion criteria
    1. Age: 18-80 years
    2. Male or female
    3. Subject is mentally able to understand the nature and content of the clinical trial and to follow the instructions of the study staff
    4. Existence of a written informed consent
    5. Diagnosis of chronic inflammatory bowel disease with indication for initial treatment with adalimumab in subjects with moderate to high grade disease activity and clinically insufficient response to or contraindication for systematic therapy with corticosteroids and/ or immunosuppressants, as defined below:
    Current diagnosis of moderate to severe, ulcerative colitis with a total Mayo score of ≥6 (endoscopic subscore of ≥2) that has been confirmed in accordance with the current guidelines of the DGVS and ECCO and has been in existence for at least 3 months.
    OR
    Current diagnosis of a moderate to severe active M. Crohn with a Harvey-Bradshaw index of ≥8 months, which has been confirmed in accordance with the current guidelines of the DGVS and ECCO and has been in existence for at least 3 months.
    AND
    insufficient response or intolerance to conventional therapy (including oral 5-ASA supplements, oral glucocorticoids, azathiopurine, 6-mercaptopurine or methothrexate)
    6. If concomitant therapy is necessary, then under the following conditions:
    a. Systemic therapy with glucocorticoids: stable dosage for at least two weeks before screening
    b. MMX budesonide (9 mg/day), stable osage for 4 weeks before screening
    c. 5-aminosalicylates: stable dosage for at least two weeks and initiated for at least 8 weeks before screening
    d. Immunosuppressants (except ciclosporin A and tacrolimus): therapy for at least three months and stable dosage for at least four weeks before screening
    7. Existence of endoscopic diagnostics taking into account the individual infestation pattern of the patient. The last endoscopic findings may have been collected no more than 12 weeks before the screening.
    8. Female participants of child bearing potential must also meet at least one of the following criteria:
    - menopause (at least 12 months of natural amenorrhea or six months of amenorrhea with serum-FSH >40mU/ml) or
    - condition after ovarectomy or hysterectomy on both sides for at least six weeks before the screening date (visit 1, day -7-6 days) or
    - Regular, correct and reliable use of a method of contraception with a failure rate of 1% per year (e.g. implants, depot syringes, intrauterine pessar, hormonal spirals) or
    - partner's vasectomy.
    1. Alter: 18-80 Jahre
    2. Männliche oder weibliche Person
    3. Der Patient ist mental in der Lage, Wesen und Inhalt der klinischen Prüfung zu verstehen und die Anweisungen des Studienpersonals zu befolgen.
    4. Vorliegen der schriftlichen Einwilligung des Patienten nach erfolgter Aufklärung durch den Prüfer bzw. ein ärztliches Mitglied der Prüfgruppe.
    5. Diagnose einer CED mit Indikation zur Neueinstellung auf Adalimumab bei mittel- bis hochgradiger Krankheitsaktivität und klinisch ungenügendem Ansprechen auf bzw. Kontraindikationen gegen eine systemische Therapie mit Glukokortikoiden und/oder Immunsuppressiva, wie folgt definiert
    Aktuelle, entsprechend den aktuellen Leitlinien der DGVS und ECCO gesicherte und mindestens seit 3 Monaten bestehende Diagnose einer mittelschweren bis schweren, aktiven Colitis ulcerosa mit einem totalen Mayo Score von ≥6 (endoskopischer Subscore von ≥2)
    ODER
    Aktuelle entsprechend den aktuellen Leitlinien der DGVS und ECCO gesicherte und mindestens seit 3 Monaten bestehende Diagnose eines mittelschweren bis schweren, aktiven M. Crohn mit einem Harvey-Bradshaw-Index von ≥8
    UND
    kein ausreichendes Ansprechen oder eine Unverträglichkeit auf eine konventionelle Therapie (einschließlich orale 5-ASA-Präparate, orale Glukokortikoide, Azathioprin, 6-Mercaptopurin oder Methothrexat)
    6. Falls Begleittherapie vorhanden, dann unter den folgenden Bedingungen:
    a. Systemische Therapie mit Glukokortikoiden: stabil über mindestens zwei Wochen vor dem Screening
    b. MMX Budesonid (9 mg/Tag), stabil seit 4 Wochen vor Screening
    c. 5-Aminosalizylate: stabile Dosierung seit mindestens zwei Wochen und initiiert seit mindestens 8 Wochen vor Screening
    d. Immunsuppressiva (außer Ciclosporin A und Tacrolimus): Therapie seit mindestens drei Monaten und dabei stabile Dosierung über mindestens vier Wochen vor Screening
    7. Vorliegen der endoskopischen Diagnostik unter Berücksichtigung des individuellen Befallsmusters des Patienten. Die letzten endoskopischen Befunde dürfen maximal 12 Wochen vor dem Screening erhoben worden sein.
    8. Teilnehmerinnen müssen zusätzlich mindestens eines der folgenden Kriterien erfüllen:
    - Menopause (mindestens zwölf Monate natürliche Amenorrhoe oder sechs Monate Amenorrhoe mit Serum-FSH >40mU/ml) oder
    - Zustand nach beidseitiger Ovarektomie oder Hysterektomie seit mindestens sechs Wochen vor dem Screening-Termin (Visite 1, Tag -7±6 Tage) oder
    - Regelmäßige, korrekte und verlässliche Anwendung einer Verhütungsmethode mit einer Fehlerquote ≤1% pro Jahr (z.B. Implantate, Depotspritzen, Intrauterinpessar, Hormonspiralen) oder
    - Vasektomie des Partners.
    E.4Principal exclusion criteria
    1. Known contraindications for adalimumab therapy:
    - Known hypersensitivity to any of the ingredients of the investigational medicinal product or to medicinal products with a similar chemical structure
    - Moderate to severe heart failure (NYHA III/IV).
    - Active tuberculosis.
    - Severe acute infection including sepsis.
    - Acute opportunistic infections including invasive fungal infections.
    2. Acute or chronic infection with hepatitis B
    3. Known demyelinating diseases of the central and peripheral nervous system (e.g. multiple sclerosis, Guillain-Barré syndrome)
    4. Malignant disease (active malignancy under ongoing oncological therapy or a recent malignancy with moderate to high risk of recurrence within the last 5 years prior to screening)
    5. The existence of another serious disease which, at the discretion of the investigator would result in a disproportionate risk to the patient concerned
    6. Pregnancy and lactation
    7. Administration of other anti-TNF-Ak therapies, ustekinumab, vedolizumab or tofacitinib within the last 4 weeks prior to study inclusion
    8. Administration of ciclosporin A or tacrolimus within the last 8 weeks prior to study inclusion in a non-stable dose
    9. Therapy with Anakinra or Abatacept
    10. Planned surgical intervention during the study period such as colectomy, installation of an ileo-anal pouche, an ileorectostomy or an ileostoma
    11. Persons who are dependent or employed by the sponsor or investigator.
    12. Planned longer stay outside the region, which prevents compliance with the visit plan.
    13. Participation in another clinical trial or administration of an unauthorised active substance within the last 4 weeks prior to the screening date.
    1. Vorliegen einer bekannten Kontraindikation für eine Therapie mit Adalimumab:
    - Bekannte Überempfindlichkeit gegenüber einem der Inhaltsstoffe des Prüfpräparats oder gegenüber Arzneimittel mit ähnlicher chemischer Struktur
    - Mäßige bis schwere Herzinsuffizienz (NYHA III/IV).
    - Aktive Tuberkulose.
    - Schwere akute Infektion einschließlich Sepsis.
    - Akute opportunistische Infektionen einschließlich invasiver Pilzinfektionen.
    2. Akute oder chronische Infektion mit Hepatitis B
    3. Bekannte demyelinisierende Erkrankungen des zentralen und peripheren Nervensystems (z.B. Multiple Sklerose, Guillain-Barré-Syndrom)
    4. Maligne Erkrankung (aktives Malignom unter laufender onkologischer Therapie oder ein rezentes Malignom mit mäßigem bis hohem Rezidivrisiko innerhalb der letzten 5 Jahre vor dem Screening)
    5. Vorliegen einer sonstigen schwerwiegenden Erkrankung, durch welche nach Ermessen des beurteilenden Arztes ein Studieneinschluss ein unverhältnismäßig hohes Risiko für den betroffenen Patienten darstellen würde
    6. Schwangerschaft und Stillzeit
    7. Gabe sonstiger anti-TNF-Ak-Therapien, Ustekinumab, Vedolizumab oder Tofacitinib innerhalb der letzten 4 Wochen vor Studieneinschluss
    8. Gabe von Ciclosporin A oder Tacrolimus innerhalb der letzten 8 Wochen vor Studieneinschluss in nicht stabiler Dosierung
    9. Therapie mit Anakinra oder Abatacept
    10. Geplanter chirurgischer Eingriff während des Studienzeitraums wie z.B. Kolektomie, Anlage eines ileo-analen Pouches, einer Ileorektostomie oder eines Ileostomas
    11. Personen, die in einen Abhängigkeits- oder Arbeitsverhältnis zum Sponsor oder Prüfer stehen.
    12. Geplanter längerer Aufenthalt außerhalb der Region, der die Einhaltung des Visitenplans verhindert.
    13. Teilnahme an einer anderen klinischen Prüfung oder Verabreichung eines nicht zugelassenen Wirkstoffs innerhalb der letzten 4 Wochen vor dem Screening-Termin.
    E.5 End points
    E.5.1Primary end point(s)
    Clinical response to adalimumab biosimilar therapy (Amgevita®) at the time 13±1 weeks after the onset of therapy in patients with moderate to severe active CED (Crohn's disease and ulcerative colitis)
    Klinisches Ansprechen auf die Therapie mit dem Adalimumab-Biosimilar (Amgevita®) zum Zeitpunkt 13±1 Wochen nach Therapiebeginn bei Patienten mit einer mittelschweren bis schweren aktiven CED (M. Crohn und Colitis ulcerosa)
    E.5.1.1Timepoint(s) of evaluation of this end point
    At the time 13±1 weeks after onset of therapy
    13±1 Wochen nach Therapiebeginn
    E.5.2Secondary end point(s)
    • Clinical response to therapy with adalimumab biosimilar (amgevita®) at time 14±3 days, 26±3 weeks, 39±3 weeks and 52±3 weeks after initiation of therapy in patients with moderate to severe active chronic IBD (Crohn's disease and ulcerative colitis)
    •Clinical remission with adalimumab biosimilar (amgevita®) at the time of 13±1 week, 26±3 weeks, 39±3 weeks and 52±3 weeks after initiation of therapy in patients with moderate to severe active IBD (Crohn's disease and ulcerative colitis)
    • Clinical response to therapy with adalimumab biosimilar (Amgevita®) at the time of 14±3 days, 26±3 weeks, 39±3 weeks and 52±3 weeks after initiation of therapy in patients with moderate to severe ulcerative colitis
    •Clinical response to therapy with adalimumab biosimilar (Amgevita®) at the time of 14±3 days, 26±3 weeks, 39±3 weeks and 52±3 weeksafter the start of therapy in patients with moderate to severe active Crohn's disease
    • Maintenance of clinical response or remission with adalimumab biosimilar (Amgevita®) in patients with IBD (Crohn's disease, ulcerative colitis) at the time of 26±3 weeks, 39±3 weeks and 52±3 weeks after the start of therapy
    • Assessment of the quality of life on the basis of the IBDQ questionnaire on the day of the start of therapy with Amgevita® (day 1) and at the time 13±1 week, 26±3 weeks, 39±3 weeks and 52±3 weeks after the start of therapy
    • Estimation of disease activity based on calprotectin concentration in the stool prior to the onset of therapy with adalimumab biosimilar (amgevita®) and at times 13±1 weeks, 26±3 weeks, and 52±3 weeks after the start of therapy
    • Adalimumab valley levels in the serum at the time of 14±3 days, 13±1, 26±3, 39±3 and 52±3 weeks after the start of therapy
    Concentration of antibodies against serum adalimumab in serum at time 14±3 days, 13±1, 26±3, 39±3 and 52±3 weeks after the start of therapy
    • Occurrence of AEs, ARs, SAEs and SARs during the observation period (day 1 after administration of the IMP up to 52±3 weeks after the start of therapy)
     Klinisches Ansprechen auf die Therapie mit Adalimumab-Biosimilar (Amgevita®) zum Zeitpunkt 14±3 Tage, 26±3 Wochen, 39±3 Wochen und 52±3 Wochen nach Therapiebeginn bei Patienten mit einer mittelschweren bis schweren aktiven CED (M. Crohn oder Colitis ulcerosa)
     Klinische Remission unter der Therapie mit Adalimumab-Biosimilar (Amgevita®) zum Zeitpunkt 13±1 Wochen, 26±3 Wochen, 39±3 Wochen und 52±3 Wochen nach Therapiebeginn bei Patienten mit einer mittelschweren bis schweren aktiven CED (M. Crohn oder Colitis ulcerosa)
     Klinisches Ansprechen auf die Therapie mit Adalimumab-Biosimilar (Amgevita®) zum Zeitpunkt 14±3 Tage, 26±3 Wochen, 39±3 Wochen und 52±3 Wochen nach Therapiebeginn bei Patienten mit einer mittelschweren bis schweren aktiven Colitis ulcerosa
     Klinisches Ansprechen auf die Therapie mit Adalimumab-Biosimilar (Amgevita®) zum Zeitpunkt 14±3 Tage, 26±3 Wochen, 39±3 Wochen und 52±3 Wochen nach Therapiebeginn bei Patienten mit einem mittelschweren bis schweren aktiven M. Crohn
     Aufrechterhaltung des klinischen Ansprechens3 bzw. Remission unter Therapie mit Adalimumab-Biosimilar (Amgevita®) bei Patienten mit einer CED (M. Crohn, Colitis ulcerosa) zum Zeitpunkt 26±3 Wochen, 39±3 Wochen und 52±3 Wochen nach Therapiebeginn
     Beurteilung der Lebensqualität anhand des IBDQ Fragebogens am Tag des Therapiebeginns mit Amgevita® (Tag 1) und zum Zeitpunkt 13±1, 26±3, 39±3 und 52±3 Wochen nach Therapiebeginn
     Abschätzung der Krankheitsaktivität anhand der Calprotectin-Konzentration im Stuhl vor Therapiebeginn mit Adalimumab-Biosimilar (Amgevita®) sowie zum Zeitpunkt 13±1, 26±3 und 52±3 Wochen nach Therapiebeginn
     Adalimumab-Talspiegel im Serum zum Zeitpunkt 14±3 Tage, 13±1, 26±3, 39±3 und 52±3 Wochen nach Therapiebeginn
     Konzentration von Antikörpern gegen Adalimumab im Serum zum Zeitpunkt 14±3 Tage, 13±1, 26±3, 39±3 und 52±3 Wochen nach Therapiebeginn
     Auftreten von AEs, ARs, SAEs und SARs im Beobachtungszeitraum (Tag 1 nach Applikation des Prüfpräparates bis 52±3 Wochen nach Therapiebeginn)
    E.5.2.1Timepoint(s) of evaluation of this end point
    14±3 days, 13±1, 26±3, 39±3 and 52±3 weeks after onset of therapy
    14±3 Tage, 13±1, 26±3, 39±3 und 52±3 Wochen nach Therapiebeginn
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 62
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state82
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    standard therapy
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-11-05
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-12-18
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA